And those who took the highest trial dose of 12 milligrams lost an average of 36.6 pounds over the study period, according to Eli Lilly
19-24 As with exenatide, there is minimal risk of hypoglycemia when used with nonsecretagogue medications
Whilst the early evidence for retatrutide liver fat reduction is scientifically promising, patients are best served by working within established NHS pathways and awaiting the outcome of robust Phase 3 trial data and formal regulatory review before drawing firm conclusions about this emerging therapy
doi:10.1038/s41398-019-0515-5 Paddon-Jones D, Westman E, Mattes RD, Wolfe RR, Astrup A, Westerterp-Plantenga M
[Stanford] Twitter: @hubermanlab Instagram: @hubermanlab
A.Loizides-MangoldU.GaaN.LazarevicV.De VitoC.et al (2021)